A study published in the journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions. The medications interact with a region of the brain—the mesolimbic system—to reduce appetite and trigger satisfaction after eating.
The mesolimbic system overlaps with the brain processes that govern addictive behaviors. This overlap suggests that GLP-1 RAs and similar medications might also alter the reward-response pathways associated with substance use. “Similar medications” include glucose-dependent insulinotropic polypeptide (GIP) agonists like the weight-loss medication Mounjaro.
Until now, most of the existing research into using GLP-1 RAs and GIPs to treat substance use disorders consists of animal studies and small-scale clinical trials.
This new large-scale human study looked at 503,747 people with a history of opioid use disorder (OUD), of which 8,103 had a prescription for a GLP-1 RA or GIP. The study found that people with OUD who had a GLP-1 RA or GIP prescription had a 40% lower rate of opioid overdose compared with those who did not have a prescription.
The study also looked at 817,309 people with a history of alcohol use disorder (AUD), of which 5,621 had a prescription for a GLP-1 RA or GIP. The study found that people with AUD who had a GLP-1 RA or GIP prescription had a 50% lower rate of alcohol intoxication compared with those who did not have a prescription.
This study may introduce a promising new treatment for substance use disorders.
More information:
Fares Qeadan et al, The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis, Addiction (2024). DOI: 10.1111/add.16679
Provided by
Society for the Study of Addiction
Citation:
Large-scale human study finds Ozempic (or similar medications) may reduce opioid overdose risk by 40% (2024, October 17)
retrieved 17 October 2024
from https://medicalxpress.com/news/2024-10-large-scale-human-ozempic-similar.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
